SkyePharma PLC (SKP.L) said it continues to trade in line with the Board's expectations for the full year.
As anticipated, the second half of 2009 is benefiting from the cost reductions which have already been implemented and the continuing effect of price increases which were negotiated in the first half of the year on a number of manufactured products.
The Group continues to hold discussions with a view to transferring the responsibility for the Flutiform supply chain to a third party. Discussions with one party have ceased and those with other parties are at a preliminary stage.
For comments and feedback: editorial@rttnews.com